Improved lentivirus recovery by weak anion exchange capture

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Purification of lentiviral vector is highly challenging due to the low stability of the enveloped virus that is sensitive to low pH, high salt, temperature, and shear forces for example. Typically, LV purification is carried out using anion exchange capture chromatography, but with low recoveries. As such, improved approaches to LV recovery underpin the potential for scalable, safe cell and gene therapy manufacture. 

In this webinar you will learn more about:

• Real world challenges in the lentiviral manufacturing workflow, with a focus on downstream processes
• Utilizing weak anion exchange capture to optimize downstream purification efficiency and vector recovery

Lisa Marx PhD

Scientist Viral Vector Applications, Cytiva

Dr. Lisa Marx is a Scientist in the Viral Vector Application group at Cytiva holding a PhD in Industrial Biotechnology. Lisa joined Cytiva in 2020, gaining experience in handling of Lentivirus, Adeno-Associated Virus, mAbs and mRNA. Her focus is on developing downstream processing and analysis of Lentivirus and thereby providing hands-on, reliable and innovative downstream solutions for gene therapy.

Watch now

SPEAKERS

Lisa Marx PhD

Scientist Viral Vector Applications, Cytiva

You might also like

Alternative solutions to separate AAV full and empty capsids using anion exchange

Åsa Hagner-McWhirter, Mark Schofield

2 April

Watch

Commercial-scale manufacture of lentivirus for ex vivo and in vivo therapies

Rachel Legmann, Michelle Yen Tran

28 March

Watch

Enhancing lentiviral vector stability and recovery: optimizing buffer formulation

Jessica Tate

7 November

Watch

Implementation of an improved platform for downstream processing of plasmid DNA

Justina Martinkeine, Klemen Božič

15 October

Watch

Overcoming the limits of lentivirus: de-risk cell therapy development with non-viral genome engineering

Miles Smith

23 April

Watch